JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Economic Benefits and Impact of Biosimilars on Healthcare System

Sailaja Gunnam[1]*, Kaunain Fathema [2], Monika Nijhawan[1], R Surya Anusha Venna[3], Rajeswari Aleti[3]

[1] *Associate Professor, Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India*
[2] *PG Scholar, Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India*
[3] *Assistant Professor, Department of Pharmaceutics, Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, India*

Publication history: Received on 23rd May 2025; Revised on 19th June 2025; Accepted on 29th June 2025

Article DOI: 10.69613/8mvctk45

Abstract: Biologics hold a significant portion of global pharmaceutical expenditure, accounting for 43% of drug costs while constituting only 2% of prescriptions in developed markets. The usage of biosimilars in healthcare systems has emerged as a crucial strategy for cost containment and improved treatment accessibility. Biosimilars show comparable safety and efficacy profiles to reference biologics, have achieved price reductions of 20-70% across various therapeutic areas. The European Union leads in biosimilar adoption, with penetration rates reaching 90% in specific therapeutic categories, while the United States market projects savings of $133 billion by 2025. Developing nations, particularly India and South Korea, have established robust biosimilar manufacturing capabilities, enhancing global access to biological therapies. However, multiple barriers impede optimal biosimilar utilization, including regulatory complexities, patent litigation, and healthcare provider hesitancy. Implementation of streamlined approval pathways, physician education programs, and value-based procurement strategies has demonstrated success in overcoming these challenges. By 2030, projected global biosimilar savings may exceed $290 billion, particularly benefiting therapeutic areas such as oncology, rheumatology, and endocrinology. The economic advantages of biosimilars extend beyond direct cost savings, enabling healthcare systems to reallocate resources, expand treatment access, and maintain long-term sustainability.

Keywords: Biosimilar economics; Healthcare cost reduction; Biological therapeutics; Market access; Treatment affordability

1. Introduction

Biological therapeutics, derived from living organisms through complex biotechnological processes, have revolutionized the treatment landscape for numerous chronic and life-threatening conditions [1]. These sophisticated molecules target specific disease pathways with remarkable precision, offering therapeutic benefits in oncology, autoimmune disorders, and metabolic diseases [2]. However, the financial implications of biologic therapies pose substantial challenges to healthcare systems worldwide. The development and manufacturing costs of biologics significantly exceed those of conventional small-molecule drugs, with treatment costs often ranging from $10,000 to $200,000 per patient annually [3]. This economic burden is particularly evident in global healthcare expenditure patterns, where biologics constitute 43% of pharmaceutical costs despite representing only 2% of prescription volumes in developed markets [4].

The advent of biosimilars has introduced a paradigm shift in biological therapy accessibility. Biosimilars are biological products that demonstrate high similarity to approved reference biologics in terms of structure, function, and clinical outcomes [5]. These alternatives undergo rigorous comparative assessments to ensure therapeutic equivalence while offering significant cost advantages due to streamlined development pathways [6]. The economic rationale for biosimilar integration extends beyond immediate cost reduction. Healthcare systems worldwide face mounting pressures from aging populations, increasing chronic disease prevalence, and limited financial resources [7]. In low and middle-income countries, where biological therapy access remains severely restricted, biosimilars present opportunities to bridge critical treatment gaps [8].

Recent market analyses indicate accelerating biosimilar adoption across therapeutic categories. The European biosimilar market, with over 15 years of experience, demonstrates the potential for sustainable cost reduction while maintaining quality healthcare delivery [9]. Emerging markets, particularly in Asia and Latin America, are developing robust biosimilar manufacturing capabilities, further expanding global access [10]. The aim of this review is to analyze the economic dynamics of biosimilar integration in healthcare systems, examining market trends, regulatory frameworks, and real-world implementation strategies.

* Corresponding author: Sailaja Gunnam

2. Rising Costs of Biologics

2.1. Development and Manufacturing Complexities

The complexity of biologic drug development demands sophisticated technological infrastructure and extensive research investment. Unlike small-molecule drugs, biologics require living cell systems for production, resulting in complex manufacturing processes [11]. The development timeline typically spans 10-15 years, with costs ranging from $1.2 to $2.5 billion per molecule [12]. Manufacturing facilities for biologics require investments exceeding $500 million, with specialized equipment and stringent environmental controls [13].

2.2. Economic Burden on Healthcare Systems

The financial impact of biologics manifests across multiple healthcare dimensions:

2.2.1. Direct Cost

Annual treatment costs for biological therapies frequently exceed $100,000 per patient, with some specialized treatments reaching $300,000 or more [14]. In oncology, biological therapies account for 70% of cancer treatment costs in developed nations [15].

2.2.2. Healthcare Budget Allocation

The disproportionate cost burden of biologics forces healthcare systems to allocate substantial portions of pharmaceutical budgets to a small patient population. Recent analyses indicate that biological therapies consume 40-45% of pharmaceutical expenditure while treating less than 2% of patients [16].

2.3. Market Dynamics and Pricing Factors

Several market-related factors contribute to sustained high prices:

2.3.1. Patent Protection

Complex patent structures, including primary and secondary patents, extend market exclusivity periods. Patent thickets, comprising multiple overlapping intellectual property rights, create significant barriers to market entry [17].

2.3.2. Limited Competition

The technical complexity and high entry barriers result in oligopolistic market conditions. Few manufacturers possess the capability and resources to develop and produce biologics, limiting competitive pressure on prices [18].

2.4. Global Healthcare System

The economic burden varies across healthcare systems:

2.4.1. Developed Markets

In nations with established healthcare systems, high biologic costs strain insurance programs and national health services. The United States experiences annual increases of 10-15% in biologic spending, affecting both public and private insurance systems [19].

Table 1. Global Comparison of Biosimilar Market Development (2020-2024)

Region	Number of Approved Biosimilars	Market Penetration Rate (%)	Average Price Reduction (%)	Therapeutic Areas
European Union	84	60-90	30-80	Oncology, Immunology, Endocrinology
United States	39	20-45	15-35	Oncology, Rheumatology
Asia-Pacific	95	35-65	40-70	Diabetes, Oncology
Latin America	28	15-30	20-45	Immunology, Endocrinology

2.4.2. Emerging Markets

Lower-income countries face severe accessibility challenges, with biological therapy often available to less than 5% of eligible patients due to cost constraints [20]. This disparity creates significant treatment gaps in regions with growing chronic disease burdens.

3. Cost-Effectiveness of Biosimilars

3.1. Biosimilar Development

The biosimilar development pathway presents significant economic advantages compared to novel biologic development. While maintaining rigorous quality standards, biosimilar development typically requires $100-200 million and 6-8 years, substantially less than reference biologics [21]. This cost efficiency stems from abbreviated development pathways that leverage existing knowledge of the reference product's safety and efficacy profile [22].

3.2. Market Competition

3.2.1. Price Reduction

Initial biosimilar market entry generally introduces 20-30% price reductions, with subsequent entrants driving further decreases [23]. European markets demonstrate mature competition patterns, with Norway achieving 69-83% price reductions for biosimilar infliximab through national tender systems. Denmark recorded 76% cost reduction in adalimumab following biosimilar introduction, while Germany documented average savings of 35% across multiple biosimilar categories [24].

3.2.2. Reference Products

The introduction of biosimilars often prompts reference product manufacturers to implement competitive pricing strategies. Analysis of European markets shows reference product price reductions of 10-30% following biosimilar entry [25].

3.3. Savings in Healthcare System

3.3.1. Direct Cost Reduction

Healthcare systems implementing structured biosimilar adoption programs report substantial savings across various regions. The European Union documented cumulative savings of €5.7 billion between 2016-2020, while United States Medicare projections indicate potential savings of $104 billion by 2024. Canadian provincial health systems achieved 25-40% reduction in biological therapy costs through systematic biosimilar integration [26, 27].

3.3.2. Resource Reallocation Benefits

Cost savings from biosimilar adoption enable healthcare systems to expand patient access to biological therapies, fund innovative treatments in other therapeutic areas, and strengthen healthcare infrastructure and services. This reallocation of resources contributes to overall healthcare system sustainability and improved patient outcomes [28].

3.4. Treatment Accessibility

3.4.1. Patient Access

Reduced treatment costs through biosimilar adoption correlate with increased patient access. European nations report 50-100% increases in biological therapy utilization, while emerging markets demonstrate two to three-fold increases in patient treatment initiation. The economic advantages of biosimilars make earlier treatment intervention more feasible across various therapeutic areas [29].

3.4.2. Healthcare Equity

Biosimilar availability particularly benefits public healthcare systems with constrained budgets, regions with limited insurance coverage, and healthcare facilities serving economically disadvantaged populations. This improved accessibility helps reduce healthcare disparities and ensures more equitable distribution of advanced biological therapies [30].

4. Regional Perspectives

4.1. European Union Experience

4.1.1. Regulatory Guidelines

The European Union established the first comprehensive regulatory pathway for biosimilars in 2004, creating a template for global markets. The European Medicines Agency (EMA) implemented science-driven approval processes focusing on comparative analytical studies, clinical efficacy, and safety assessments [31]. This regulatory clarity has facilitated rapid market penetration and widespread adoption across member states.

4.1.2. Market Performance

Nordic countries lead biosimilar adoption, with Norway and Denmark achieving market penetration rates exceeding 90% for key molecules. The success stems from centralized procurement systems, physician incentive programs, and robust pharmacovigilance networks [32]. Germany's multi-stakeholder approach, combining prescription quotas with educational initiatives, resulted in biosimilar market shares of 65-85% across different therapeutic categories [33].

4.2. Regulatory Evolution in United States

The U.S. Food and Drug Administration's implementation of the Biologics Price Competition and Innovation Act created a defined pathway for biosimilar approval. Despite initial delays, accelerated approval processes have enabled 39 biosimilar authorizations by 2024 [34]. The introduction of interchangeability designations has further enhanced market confidence and adoption rates. The U.S. biosimilar market demonstrates unique characteristics influenced by complex reimbursement systems and patent litigation. Initial uptake faced challenges from contracting practices and rebate structures. However, recent policy reforms and increased payer acceptance have accelerated adoption, particularly in oncology and immunology sectors [35].

4.3. Asian Markets

India and South Korea have emerged as global biosimilar manufacturing centers, leveraging cost-effective production capabilities and supportive regulatory environments. Indian manufacturers have commercialized over 100 biosimilar products, focusing on affordability and widespread access [36].

China's biosimilar sector has undergone rapid transformation following regulatory reforms. The implementation of the Marketing Authorization Holder system and alignment with international standards has attracted significant investment in biosimilar development and manufacturing infrastructure [37].

4.4. Emerging Markets

4.4.1. Latin America

Brazil and Mexico have established biosimilar-specific regulatory pathways, emphasizing local manufacturing capacity development. These markets demonstrate increasing biosimilar penetration, particularly in government healthcare programs [38].

4.4.2. Middle East and Africa

Regional variation in regulatory requirements and healthcare infrastructure affects biosimilar adoption. Countries like Saudi Arabia and South Africa have implemented abbreviated approval pathways, while others continue developing regulatory frameworks [39].

4.5. Clinical and Economic Outcomes

Post-marketing surveillance data from multiple regions confirms comparable efficacy and safety profiles between biosimilars and reference products. Long-term studies in rheumatology and oncology demonstrate maintained therapeutic outcomes following switching to biosimilars [40]. Real-world economic analyses validate projected cost savings. Healthcare systems report 15-45% reduction in treatment costs across various therapeutic areas, with additional benefits from increased competition and market efficiency [41]

5. Barriers to Biosimilar Adoption

5.1. Stakeholder-Specific Challenges

Medical practitioners often express reservations regarding biosimilar implementation. Primary concerns include immunogenicity risks, clinical equivalence across indications, and the complexity of biological product comparability [42]. Survey data indicates that 35% of physicians report insufficient confidence in biosimilar prescribing, particularly in sensitive therapeutic areas such as oncology [43]. Patient acceptance remains variable, influenced by several critical factors. Limited understanding of biosimilar concepts presents a significant barrier, along with concerns about switching from established treatments. Many patients maintain perceptions of biosimilars as inferior alternatives to reference products. Studies indicate that structured patient education programs significantly improve acceptance rates, with informed patients showing 80% higher willingness to accept biosimilar treatments [44].

5.2. Structural Impediments

Complex reimbursement systems and formulary policies can impede biosimilar market entry. Existing contracting practices often favor reference products through rebate structures and exclusive arrangements. Analysis of U.S. markets reveals that formulary placement significantly influences biosimilar adoption rates, with restricted access reducing uptake by 40-60% [45].



Figure 1. Implementation of Biosimilar Process in Healthcare Systems

Healthcare facilities require substantial infrastructure adaptation for biosimilar integration. This includes comprehensive modifications to electronic health record systems, extensive supply chain management adjustments, and development of staff training programs. These implementation costs can delay adoption, particularly in resource-limited settings [46].

5.3. Legal Challenges

Intellectual property disputes continue to affect biosimilar market entry. Patent thickets and litigation strategies delay commercialization, with average delays of 12-18 months reported in major markets. Legal proceedings add significant costs to biosimilar development and marketing efforts, creating additional barriers to market entry [47].

Despite maturing regulatory frameworks, challenges persist in various areas of biosimilar regulation. Interchangeability designations remain a complex issue, while naming conventions and post-marketing surveillance requirements continue to evolve. International regulatory harmonization remains incomplete, complicating global development programs and market access strategies [48].



Figure 2. Barriers to Biosimilar Adoption in Healthcare Systems

5.4. Economic Barriers

While lower than reference product development, biosimilar programs require substantial investment. Development costs ranging from $100-200 million create entry barriers for smaller manufacturers and limit competition in some therapeutic categories. This financial burden restricts market participation and potentially reduces competitive pressure on prices [49].

Biological manufacturing complexity presents ongoing challenges in the biosimilar sector. Scale-up difficulties, stringent process validation requirements, and intensive quality control demands create significant operational hurdles. These factors contribute to higher production costs and potential supply constraints, affecting market stability and adoption rates [50].

Table 2. Barriers and Factors in Biosimilar Adoption

Stakeholder	Primary Barriers	Factors	Implementation
Healthcare Providers	Clinical uncertainty, Limited experience	Evidence-based education, Clinical guidelines	Peer education programs, Practice protocols
Patients	Safety concerns, Treatment switching anxiety	Clear communication, Support programs	Patient education materials, Advocacy engagement
Payers	Cost-benefit uncertainty, Implementation costs	Economic analysis, Risk-sharing models	Value-based contracts, Monitoring systems
Healthcare Systems	Infrastructure limitations, Process changes	Systematic planning, Resource allocation	Phased implementation, Staff training

5.5. Knowledge Gaps

Healthcare provider education regarding biosimilar science and clinical applications remains inconsistent across markets and specialties. Studies indicate significant variation in understanding of key concepts such as extrapolation of indications and immunogenicity assessment. This knowledge gap affects confidence in prescribing and implementing biosimilar therapies [51]. Limited public understanding of biosimilars affects acceptance and uptake across healthcare systems. Communication challenges persist regarding the technical complexity of biological medicines and common misconceptions about generic equivalence. The variable quality of information available in public domains further complicates patient education and acceptance [52].

6. Integration of Biosimilars

Successful biosimilar integration requires streamlined regulatory processes that maintain scientific rigor while facilitating efficient market entry. Leading regulatory authorities have implemented adaptive licensing pathways incorporating real-world evidence and abbreviated clinical development programs. These approaches reduce development timelines while ensuring product quality and patient safety [53].

Healthcare systems have developed various economic mechanisms to encourage biosimilar adoption. Value-based procurement systems, prescribing incentives, and gain-sharing arrangements between providers and payers have demonstrated effectiveness in multiple markets. The Norwegian tender system, for example, has achieved remarkable cost reductions while maintaining high-quality care standards [54].

Comprehensive healthcare provider engagement strategies focus on evidence-based education and practical implementation support. Successful programs incorporate clinical data presentation, peer-to-peer learning networks, and practical guidance for patient management. Hospital systems implementing structured provider education report significantly higher biosimilar adoption rates and provider satisfaction [55].

Table 3. Regulatory Guidelines and Approval Across Major Markets

Regulatory Guidelines	EMA (European Union)	FDA (United States)	PMDA (Japan)	NMPA (China)
Analytical Studies	Comprehensive characterization	Comprehensive characterization	Comprehensive characterization	Comprehensive characterization with local standards
Non-clinical Studies	Abbreviated package	Abbreviated package	Full package required	Full package with local studies
Clinical Studies Required	Phase I PK/PD Phase III in one indication	Phase I PK/PD Phase III in one indication	Phase I and III with local population	Phase I and III with local population
Extrapolation of Indications	Permitted with justification	Permitted with justification	Limited permission	Case-by-case basis
Interchangeability Designation	National level decisions	Specific designation pathway	Not available	Not available
Review Timeline	210 days	10 months	12 months	12-18 months

Effective patient communication strategies emphasize transparency and shared decision-making. Educational materials tailored to patient literacy levels, combined with consistent messaging across healthcare teams, improve treatment acceptance. Patient advocacy group engagement has proven valuable in building trust and understanding within patient communities [56].

Successful biosimilar programs typically follow a phased implementation approach. Initial focus on specific therapeutic areas or patient populations allows healthcare systems to develop expertise and confidence. Electronic health record integration, standardized switching protocols, and robust pharmacovigilance systems support safe and efficient adoption [57].

Professional societies and healthcare organizations have developed specific guidelines for biosimilar use. These guidelines address practical aspects of patient selection, monitoring requirements, and management of treatment transitions. Regular updates incorporating real-world experience enhance clinical confidence and standardize practice patterns [58].

Innovative procurement approaches balance cost savings with supply chain stability. Multi-winner tender systems, long-term contracts, and regional purchasing collaboratives have demonstrated success in various markets. These strategies ensure competitive pricing while maintaining manufacturer interest and investment [59]. Efficient distribution systems are crucial for biosimilar market success. Investment in cold chain infrastructure, inventory management systems, and healthcare facility storage capabilities supports reliable product access. Strategic partnerships between manufacturers, distributors, and healthcare providers enhance supply chain resilience [60].



Figure 3. Global Implementation of Biosimilars

Comprehensive monitoring programs track clinical outcomes, economic impacts, and implementation challenges. Data collection systems incorporating patient registries, electronic health records, and claims databases provide evidence for program optimization. Regular analysis and reporting support continuous improvement and stakeholder confidence [61]. Robust quality assurance programs address product handling, administration protocols, and adverse event monitoring. Standard operating procedures, staff training programs, and regular audits ensure consistent service delivery. Integration with existing pharmacovigilance systems strengthens safety monitoring and risk management [62].

7. Conclusion

Biosimilar adoption generates substantial economic benefits across healthcare systems. Documented cost reductions of 20-80% demonstrate the potential for significant healthcare budget optimization. These savings enable broader patient access to biological therapies and release resources for other healthcare priorities. Real-world experience, particularly from mature markets like the European Union, confirms that properly regulated biosimilars maintain therapeutic effectiveness while improving healthcare system sustainability. The accumulated clinical evidence over the past decade provides robust support for biosimilar safety and efficacy. Successful biosimilar integration requires coordinated effort across multiple stakeholders. The most effective implementation programs combine regulatory efficiency, stakeholder education, and practical support systems. Healthcare systems that have achieved high biosimilar adoption rates consistently demonstrate strong institutional commitment and comprehensive support structures. In conclusion, biosimilars are crucial for addressing the economic challenges of modern healthcare while maintaining

therapeutic standards. Their successful integration requires sustained commitment to evidence-based implementation strategies and stakeholder engagement.

References

[1] Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018;36(12):1136-1145.

[2] Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21(16):s331-s340.

[3] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33.

[4] IQVIA Institute for Human Data Science. Global Medicine Spending and Usage Trends: Outlook to 2025. IQVIA; 2021.

[5] Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671-677.

[6] Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.

[7] WHO. Access to biotherapeutic products including similar biotherapeutic products and ensuring their quality, safety and efficacy. WHO Technical Report Series. 2019;1004:71-152.

[8] Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in Central and Eastern European countries. Front Pharmacol. 2017;8:288.

[9] Moorkens E, Vulto AG, Huys I, et al. Policies for biosimilar uptake in Europe: An overview. PLoS One. 2017;12(12):e0190147.

[10] Kumar R, Singh V. Biosimilars: regulatory status and implications across the world. Syst Rev Pharm. 2020;11(4):403-410.

[11] Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469-478.

[12] Morgan S, Grootendorst P, Lexchin J, et al. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4-17.

[13] Farid SS. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B. 2007;848(1):8-18.

[14] Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160-2172.

[15] Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260-1265.

[16] Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3-12.

[17] Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff. 2015;34(2):302-310.

[18] Troein P, Newton M, Scott K. The impact of biosimilar competition in Europe. IQVIA Report. 2020;1-36.

[19] Medicare Payment Advisory Commission. Report to the Congress: Medicare and the Health Care Delivery System. Washington, DC: MedPAC; 2019.

[20] Kostic M, Djakovic L, Sujic R, et al. Inflammatory bowel diseases (IBD): access to biologic therapies in emerging countries. Front Pharmacol. 2017;8:725.

[21] Blackstone EA, Fuhr JP Jr. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469-478.

[22] Tkaczuk KHR, Jacobs IA. Biosimilars in oncology: from development to clinical practice. Semin Oncol. 2014;41(suppl 3):S3-S12.

[23] Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: Part 1-Biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285-297.

[24] Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902-903.

[25] Vogler S, Schneider P, Panteli D, et al. Evolution of prices of biological medicines in European countries and their implications. Front Pharmacol. 2021;12:625296.

[26] IQVIA Institute for Human Data Science. The Impact of Biosimilar Competition in Europe. 2021.

[27] Mulcahy AW, Hlavka JP, Case SR. Biosimilars in the United States: Current Status and Future Implications. RAND Corporation; 2020.

[28] Simoens S, Jacobs I, Popovian R, et al. Assessing the value of biosimilars: a review of the role of budget impact analysis. PharmacoEconomics. 2017;35(10):1047-1062.

[29] Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34(2):159-170.

[30] McKinnon R, Cook M, Liauw W, et al. Biosimilarity and Interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32(1):27-52.

[31] Kurki P, van Aerts L, Wolff-Holz E, et al. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83-91.

[32] Olsen IC, Haavardsholm EA, Moholt E, et al. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre cohort. Arthritis Rheumatol. 2016;68(suppl 10).

[33] Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11(6):690-696.

[34] FDA. Biosimilar Product Information. FDA-Approved Biosimilar Products [Internet]. 2024 [accessed 2024 Jan 15].

[35] Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463-478.

[36] Kumar R, Sigala S, Malhotra HD, et al. Biosimilars: Regulatory status and implications across the world. Syst Rev Pharm. 2020;11(4):403-410.

[37] Li J, Yang C, Xia Y, et al. Biosimilars in China: current status and future perspectives. MAbs. 2019;11(6):992-1003.

[38] de la Mora-Molina H, Hernández-Gálvez G, García-García JA, et al. Pharmacovigilance challenges for biosimilars in Latin America. Front Pharmacol. 2021;12:634417.

[39] Al-Sabbagh A, Olech E, McCarter JE, et al. Development of biosimilars in an era of oncologic drug shortages. Drug Des Devel Ther. 2019;13:3591-3597.

[40] Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192-200.

[41] Moorkens E, Vulto AG, Huys I. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? MAbs. 2020;12(1):1743517.

[42] Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33(12):2160-2172.

[43] Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32(7):681-691.

[44] van Overbeeke E, De Beleyr B, de Hoon J, et al. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs. 2017;31(5):447-459.

[45] Smeeding J, Malone DC, Ramchandani M, et al. Biosimilars: considerations for payers. P T. 2019;44(2):54-63.

[46] Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards biosimilar medicines: A systematic review. PLoS One. 2017;12(12):e0189399.

[47] Holzmann J, Balser S, Windisch J. Totality of evidence in the development of ABP 501, the first biosimilar monoclonal antibody. BioDrugs. 2016;30(1):1-11.

[48] Declerck P, Bakalos G, Zintzaras E, et al. Monoclonal antibody biosimilars in oncology: critical appraisal of available data on switching. Clin Ther. 2018;40(5):798-809.

[49] Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469-478.

[50] Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology. 2017;56(suppl_4):iv14-iv29.

[51] Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020;34(4):407-414.

[52] Jacobs I, Singh E, Sewell KL, et al. Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence. 2016;10:937-948.

[53] Kurki P, Barry S, Bourges I, et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: A regulatory perspective. Drugs. 2021;81(16):1881-1896.

[54] Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070.

[55] Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463-478.

[56] Barbier L, Simoens S, Vulto AG, et al. European stakeholder learnings regarding biosimilars: Part I-improving biosimilar understanding and adoption. BioDrugs. 2020;34(6):783-796.

[57] Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34(2):159-170.

[58] Kay J, Schoels MM, Dörner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165-174.

[59] Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: Part 1-Biosimilar and originator infliximab in the hospital setting. BioDrugs. 2019;33(3):285-297.

[60] Rémuzat C, Kapuśniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315.

[61] McKinnon RA, Cook M, Liauw W, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32(1):27-52.

[62] Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671-677.